Marecko Ilona, Cvejic Dubravka, Selemetjev Sonja, Paskas Svetlana, Tatic Svetislav, Paunovic Ivan, Savin Svetlana
Svetlana Savin, Institute for the Application of Nuclear Energy - INEP, University of Belgrade, Banatska 31b, 11080 Zemun - Belgrade, Serbia,
Croat Med J. 2014 Apr;55(2):128-37. doi: 10.3325/cmj.2014.55.128.
To determine whether matrix metalloproteinase-9 (MMP-9) may be a useful adjunctive tool for predicting unfavorable biological behavior of papillary thyroid carcinoma (PTC) by evaluating the expression profile and proteolytic activity of MMP-9 in PTC by different techniques and correlating the findings with clinicopathological prognostic factors.
Immunohistochemical localization of MMP-9 was analyzed with antibodies specific for either total or active MMP-9. Activation ratios of MMP-9 were calculated by quantifying gel zymography bands. Enzymatic activity of MMP-9 was localized by in situ zymography after inhibiting MMP-2 activity.
Immunostaining of total and active MMP-9 was observed in tumor tissue and occasionally in non-neoplastic epithelium. Only active MMP-9 was significantly associated with extrathyroid invasion, lymph-node metastasis, and the degree of tumor infiltration (P<0.001, P=0.004, and P<0.001, respectively). Gelatin zymography revealed a correlation between the MMP-9 activation ratio and nodal involvement, extrathyroid invasion, and the degree of tumor infiltration. In situ zymography showed that gelatinases exerted their activity in tumor parenchymal and stromal cells. Moreover, after application of MMP-2 inhibitor, the remaining gelatinase activity, corresponding to MMP-9, was highest in cancers with the most advanced degree of tumor infiltration.
This is the first report suggesting that the evaluation of active MMP-9 by immunohistochemistry and determination of its activation ratio by gelatin zymography may be a useful adjunct to the known clinicopathological factors in predicting tumor behavior. Most important, in situ zimography with an MMP-2 inhibitor for the first time demonstrated a strong impact of MMP-9 activity on the degree of tumor infiltration during PTC progression.
通过不同技术评估基质金属蛋白酶-9(MMP-9)在甲状腺乳头状癌(PTC)中的表达谱和蛋白水解活性,并将结果与临床病理预后因素相关联,以确定MMP-9是否可能是预测PTC不良生物学行为的有用辅助工具。
用针对总MMP-9或活性MMP-9的特异性抗体分析MMP-9的免疫组织化学定位。通过定量凝胶酶谱带计算MMP-9的激活率。在抑制MMP-2活性后,通过原位酶谱法定位MMP-9的酶活性。
在肿瘤组织中观察到总MMP-9和活性MMP-9的免疫染色,偶尔在非肿瘤上皮中也有观察到。仅活性MMP-9与甲状腺外侵犯、淋巴结转移和肿瘤浸润程度显著相关(分别为P<0.001、P=0.004和P<0.001)。凝胶酶谱显示MMP-9激活率与淋巴结受累、甲状腺外侵犯和肿瘤浸润程度之间存在相关性。原位酶谱显示明胶酶在肿瘤实质细胞和基质细胞中发挥活性。此外,应用MMP-2抑制剂后,对应于MMP-9的剩余明胶酶活性在肿瘤浸润程度最高的癌症中最高。
这是首次报道表明,通过免疫组织化学评估活性MMP-9并通过凝胶酶谱法测定其激活率可能是预测肿瘤行为的已知临床病理因素的有用辅助手段。最重要的是,首次使用MMP-2抑制剂的原位酶谱法证明了MMP-9活性对PTC进展过程中肿瘤浸润程度有强烈影响。